Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline

Publisher’s latest report, "Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline" is a comprehensive, granular analysis of the 20,756 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications. This pipeline is also benchmarked against its size across each segment in 2015, and an assessment of the level of first-in-class innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.

Innovation, particularly the development of new products, is a crucial element of the pharmaceutical industry. The market is highly research-intensive, being deeply reliant on a high level of R&D investment and a strong product pipeline to maintain growth and ensure long-term revenue generation. Without successful innovation, which can be broadly defined as the market launch of novel therapeutic molecules that cost-effectively treat or cure diseases, the industry would face a substantial long-term decline in revenue.

Get Sample Copy of Report@ http://www.reportsweb.com/inquiry&RW00020620/sample

A particular focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation. Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily each year since 1994, with the exception of the years 2005-2008, when the proportion was relatively high.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 5
2.1 Increasing Cost of Drug Development 7
2.2 Most Drugs Fail to Recuperate R&D Costs 8
2.3 Contracting Life Cycles for Approved Products 9
2.4 The Case for First-in-Class Pharmaceutical Innovation 10
2.5 Conclusion 13

Get More Information@ http://www.reportsweb.com/innovation-tracking-factbook-2016-an-assessment-of-the-pharmaceutical-pipeline

3 Assessment of the Pharmaceutical Industry Pipeline 14
3.1 Pipeline and Clinical Trials Landscape by Therapy Area 14
3.2 Pipeline by Stage of Development 19
3.3 Pipeline by Molecule Type 22
3.4 Key Therapy Areas by Indication 26
3.4.1 Oncology 26
3.4.2 Infectious Diseases 28
3.4.3 Central Nervous System 29
3.4.4 Immunology 32
3.5 Conclusion 33
4 Assessment of Innovation in the Pharmaceutical Industry Pipeline 34
4.1 First-in-Class Innovation by Stage of Development 36
4.2 Key Therapy Areas by Indication 38
4.2.1 Oncology 38
4.2.2 Infectious Diseases 41
4.2.3 Central Nervous System 43
4.2.4 Immunology 47
4.3 Conclusion 49
5 Company Analysis 50
5.1 Conclusion 54
6 Deals Analysis 55
6.1 Licensing Deals 55
6.2 Co-development Deals 60
6.3 Mergers and Acquisitions 65
6.4 Capital Raising 67

Buy This Report@ http://www.reportsweb.com/buy&RW00020620/buy/2995

7 Appendix 69
7.1 References 69
7.2 Contact Us 70
7.3 Disclaimer 70

About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

This release was published on openPR.